Celldex Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.9%projected annual EPS growth
Analyst Coverage
15analysts covering
FY EPS (est.)
-$4.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Phase 3 CSU Topline Data Announcement | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Barzolvolimab Phase 3 CSU (EMBARQ-CSU 1 and 2) Enrollment Status Annually1.9KTarget: Completed (1,939 patients enrolled across 43 countries)
Cash Runway (Years of Funding) Quarterly2.5Target: Fund operations through 2028
Quarterly Research and Development (R&D) Expenses Quarterly73MTarget: Accelerated late-stage development of barzolvolimab
Watch Items
- Barzolvolimab Phase 3 Chronic Spontaneous Urticaria (CSU) Topline Data ReadoutTrigger: Q4 2026Action: Evaluate efficacy (reduction in hives/itch) and safety profile compared to standard of care (Xolair) and competitors (remibrutinib).
- Biologics License Application (BLA) Submission for Barzolvolimab in CSUTrigger: 2027 Calendar YearAction: Monitor regulatory filing preparations and pre-commercialization activities following positive Phase 3 data.
- Phase 2 Clinical Readouts for Barzolvolimab in Prurigo Nodularis (PN) and Atopic Dermatitis (AD)Trigger: Late 2026Action: Assess multi-indication expansion potential to justify long-term valuation multiples.
- CDX-622 Bispecific Antibody Phase 1 Proof of Mechanism Data in AsthmaTrigger: Ongoing 2026Action: Analyze safety, target engagement, and mast cell depletion signals to validate the broader bispecific platform.
Research as of 20 Jun 2026